Aarti Pharmalabs' Q1 FY 2025-26 Quarterly Results

Result Summary

• Aarti Pharmalabs Ltd reported a 23.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 30.5%.
• Its expenses for the quarter were down by 22.2% QoQ and 33.8% YoY.
• The net profit decreased 24.1% QoQ and decreased 10.7% YoY.
• The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 5.5 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aarti Pharmalabs Ltd is engaged in the pharmaceutical industry, with a focus on manufacturing and supplying various pharmaceutical ingredients and products. The company operates within a competitive marketplace, contributing to the healthcare sector through its products. As of the provided data, there are no specific mentions of recent major developments within the company. For a detailed understanding of any recent changes or strategic moves, further research beyond the given data would be necessary.

Revenue

In the first quarter of the fiscal year 2026 (Q1FY26), Aarti Pharmalabs Ltd reported a total income of ₹387.79 crores. This marks a quarter-over-quarter (QoQ) decrease of 23.6% from ₹507.80 crores in Q4FY25. Compared to the same quarter in the previous year (Q1FY25), where the revenue was ₹557.71 crores, the total income decreased by 30.5% year-over-year (YoY). The decline in revenue both QoQ and YoY suggests a significant reduction in sales or other income streams for the company during this period.

Profitability

The profit before tax for Q1FY26 was ₹67.25 crores, which is a decrease of 29.8% QoQ from ₹95.75 crores in Q4FY25. On an annual comparison, this figure represents an 8.7% decline from ₹73.68 crores in Q1FY25. The tax expense for Q1FY26 was ₹15.95 crores, showing a 47.7% reduction QoQ and a 12.5% decrease YoY. Consequently, the profit after tax stood at ₹49.50 crores, down by 24.1% from the previous quarter's ₹65.25 crores, and by 10.7% from the ₹55.45 crores recorded in Q1FY25. The earnings per share (EPS) also experienced a decline, with a QoQ reduction of 23.6% and a YoY decrease of 9.8%.

Operating Metrics

Aarti Pharmalabs Ltd's total expenses for Q1FY26 were ₹320.53 crores, marking a 22.2% decrease from ₹412.05 crores in Q4FY25, and a 33.8% decrease from ₹484.03 crores in Q1FY25. The reduction in total expenses might indicate a decrease in operational activities or cost-cutting measures. However, despite the reduction in expenses, the profit margins were affected, as shown by the declines in profit before tax and profit after tax. The financial data suggest changes in operational efficiency or shifts in cost structures during this period. Further insights into the company's financial ratios, such as P/E ratio, debt-to-equity ratio, or current ratio, are not provided within the data, which would otherwise aid in a more detailed operational analysis.